A selective tumor microvasculature thrombogen that targets a novel receptor complex in the tumor angiogenic microenvironment

Cancer Research

Volumn 65, Issue 23, 2005, Pages 11109-11117

  El Sheikh, Amr ^a   Borgstrom, Per ^b   Bhattacharjee, Gourab ^a   Belting, Mattias ^a,c   Edgington, Thomas S ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; CHONDROITIN 6 SULFATE; HEPARIN; NEUROPILIN 1; PROTEOGLYCAN; PROTHROMBIN; THROMBOPLASTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFARCTION; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOGENESIS; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; HEPARIN; MALE; MICE; MICE, INBRED BALB C; NECROSIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SPHEROIDS, CELLULAR; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 28244486499     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2733     Document Type: Article

References (39)

1. El-Sheikh A, Liu C, Huang H, Edgington TS. A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium. Cancer Res 2002;62:7118-23.
2. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65.
3. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
4. Soker S, Kaefer M, Johnson M, Klagsbrun M, Atala A, Freeman MR. Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype. Am J Pathol 2001;159:651-9.
5. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14:2532-9.
6. Halder JB, Zhao X, Soker S, et al. Differential expression of VEGF isoforms and VEGF(164)-specific receptor neuropiiin-1 in the mouse uterus suggests a role for VEGF(164) in vascular permeability and angiogenesis during implantation. Genesis 2000;26: 213-24.
7. Miao HQ, Klagsbrun M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev 2000;19:29-37.
8. Klagsbrun M, Takashima S, Mamluk R. The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 2002;515:33-48.
9. Vanveldhuizen PJ, Zulfiqar M, Banerjee S, et al. Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol Rep 2003;10: 1067-71.
10. Gu C, Limberg BJ, Whitaker GB, et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J Biol Chem 2002;277:18069-76.
11. Whitaker GB, Limberg BJ, Rosenbaum JS. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121).J Biol Chem 2001;276:25520-31.
12. Soker S, Miao HQ, Nomi M, Takashima S, Klagsbrun M. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 2002;85: 357-68.
13. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem 2002;277: 24818-25.
14. Stone MJ, Ruf W, Miles DJ, Edgington TS, Wright PE. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization. Biochem J 1995; 310:605-14.
15. Donate F, Kelly CR, Ruf W, Edgington TS. Dimerization of tissue factor supports solution-phase autoactivation of factor VII without influencing proteolytic activation of factor X. Biochemistry 2000;39:11467-76.
16. Ruf W, Edgington TS. An anti-tissue factor monoclonal antibody which inhibits TF VIIa complex is a potent anticoagulant in plasma. Thromb Haemost 1991;66:529-33.
17. Lehr HA, Leunig M, Menger MD, Nolte D, Messmer K. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol 1993;143:1055-62.
18. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-9.
19. Soker S, Fidder H, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 1996;271:5761-7.
20. Soker S, Gollamudi-Payne S, Fidder H, Charmahelli H, Klagsbrun M. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165. J Biol Chem 1997;272:31582-8.
21. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993;72:835-46.
22. Costa C, Soares R, Schmitt F. Angiogenesis: now and then. APMIS 2004;112:402-12.
23. Parikh AA, Fan F, Liu WB, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004;164: 2139-51.
24. Parikh AA, Liu WB, Fan F, et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer 2003; 98:720-9.
25. Akagi M, Kawaguchi M, Liu W, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 2003;88:796-802.
26. Fukahi K, Fukasawa M, Neufeld G, Itakura J, Korc M. Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 2004;10:581-90.
27. Chen C, Li M, Chai H, Yang H, Fisher WE, Yao Q. Roles of neuropilins in neuronal development, angiogenesis, and cancers. World J Surg 2005;29:271-5.
28. Mac Gabhann F, Popel AS. Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol 2005;288:H2851-60.
29. Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997;14:2079-89.
30. Goulas A, Papakonstantinou E, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Hatzichristou DG. Tissue structure-specific distribution of glycosaminoglycans in the human penis. Int J Biochem Cell Biol 2000;32:975-82.
31. Goulas A, Hatzichristou DG, Karakiulakis G, Mirtsou-Fidani V, Kalinderis A, Papakonstantinou E. Benign hyperplasia of the human prostate is associated with tissue enrichment in chondroitin sulphate of wide size distribution. Prostate 2000;44:104-10.
32. Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 1995; 15:2107-12.
33. Tsara ME, Theocharis AD, Theocharis DA. Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res 2002;22:2893-8.
34. Theocharis AD, Tsara ME, Papageorgakopoulou N, Vynios DH, Theocharis DA. Characterization of glycosaminoglycans from human normal and scoliotic nasal cartilage with particular reference to dermatan sulfate. Biochim Biophys Acta 2001;1528:81-8.
35. Theocharis AD, Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta 2000;1502:201-6.
36. Schwartz NB, Domowicz M. Chondrodysplasias due to proteoglycan defects. Glycobiology 2002;12:57-68R.
37. Domowicz M, Mangoura D, Schwartz NB. Cell specific-chondroitin sulfate proteoglycan expression during CNS morphogenesis in the chick embryo. Int J Dev Neurosci 2000;18:629-41.
38. Bates D, Taylor GI, Minichiello J, et al. Neurovascular congruence results from a shared patterning mechanism that utilizes semaphorin3A and neuropilin-1. Dev Biol 2003;255:77-98.
39. Fair DS. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 1983;62:784-91.